BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Europabio - ECPv6.17.2//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.europabio.org
X-WR-CALDESC:Events for Europabio
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Brussels
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20200329T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20201025T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20210328T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20211031T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20220327T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20221030T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210301T093000
DTEND;TZID=Europe/Brussels:20210302T170000
DTSTAMP:20210212T163133Z
CREATED:20210203T211251Z
LAST-MODIFIED:20210212T163133Z
UID:1150-1614591000-1614704400@www.europabio.org
SUMMARY:1st International Conference on Rare Diseases
DESCRIPTION:1st International Conference on Rare Diseases \n\n\n\nDifferent infrastructures and organisational arrangements are required in each country to address the healthcare needs of its rare disease population in an effective way. Whether a single rare disease affects thousands or only a handful of individuals\, they all share similar challenges to get a timely diagnosis\, face the same barriers to access highly specialized care and treatment options and need to deal with a substantial psychosocial burden. \n\n\n\nThe health of people living with a rare disease should not be left to luck or chance especially amidst the COVID-19 pandemic. Planning ahead requires all stakeholders to acknowledge their individual responsibility to build a successful pathway from diagnosis to access and at the same time\, commit to work together in a much more agile and coordinated way than what we have seen so far. If we fail to do so\, we will have failed the 30 million people living with a rare disease in Europe. \n\n\n\nThe 1st International Conference on Rare Diseases “Building a Pathway from Diagnosis to Access” recognises that the next decade holds great potential for improvement and that while we cannot predict the future\, we all have a role in preparing for it. As the EU shapes its future regulations\, strategies and access policies\, this conference will serve as an opportunity to press the ‘pause button’ and take the time to co-create policy options today that can lead to a better patient journey in the future. \n\n\n\nEngaging all stakeholders to take action\, the 1st International Conference on Rare Diseases aspires to bring together all stakeholders in the rare disease community – patient representatives\, policy makers\, clinicians\, researchers\, industry representatives\, payers and regulators to exchange invaluable knowledge with the aim to enhance dialogue and promote policy changes to help build a better pathway from Diagnosis to Access for Rare Diseases.
URL:https://www.europabio.org/event/1st-international-conference-on-rare-diseases/
LOCATION:VIRTUAL\, 338. Kleisthenous Str.\, Gerakas\, Attiki\, 15344\, Greece
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Rare-Diseases.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210302T090000
DTEND;TZID=Europe/Brussels:20210305T170000
DTSTAMP:20210212T163115Z
CREATED:20210209T163156Z
LAST-MODIFIED:20210212T163115Z
UID:1278-1614675600-1614963600@www.europabio.org
SUMMARY:Oncology Virtual Partnering (Member Discount)
DESCRIPTION:Oncology is one of the most challenging areas for research and development\, but there are critical junctures where the right environment is crucial for success – and where partnering can help bring the best science forward. \n\n\n\nAt Inova\, our aim is to facilitate the bridge between science and business. Inova and Biotechnology Innovation Organization (BIO)\, in partnership with Evaluate\, are organizing this Oncology Virtual Partnering Event. Through online one-to-one meetings taking place 2 – 5 March\, researchers\, biotechs and biopharmaceutical companies will discuss the latest research from oncology congresses\, pitch ideas and partner to prioritize the most promising research efforts. \n\n\n\nThis event will leverage Inova and Biotechnology Innovation Organization (BIO)’s biopharma industry expertise\, leading digital networking platform and years of experience organizing partnering events to connect scientific and business communities for the benefit of patients worldwide. \n\n\n\n\n\n\n\nEuropaBio Members can benefit from 15% discount. Please liaise with Martina Cilia for further details.
URL:https://www.europabio.org/event/oncology-virtual-partnering-member-discount/
LOCATION:VIRTUAL\, Inova Software\, 89 Rue Tronchet\, Lyon\, 69006\, France
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Oncology.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210303T084500
DTEND;TZID=Europe/Brussels:20210303T121500
DTSTAMP:20210212T163056Z
CREATED:20210203T212715Z
LAST-MODIFIED:20210212T163056Z
UID:1157-1614761100-1614773700@www.europabio.org
SUMMARY:Annual Conference on EU Law in the Pharmaceutical Sector
DESCRIPTION:Annual Conference on EU Law in the Pharmaceutical Sector (3-5 March 2021) \n\n\n\nObjective \n\n\n\nThis online conference will bring legal practitioners working with the pharmaceutical sector up-to-date on the latest relevant regulatory developments\, legislative initiatives and case law. \n\n\n\nKey topics \n\n\n\nImpact of recent rulings from the CJEU on supplementary protection certificates\, patent settlements\, and online sales of medicinal products Ongoing European Commission cases on competition lawTowards a European Health Data SpaceThe European Commission’s Pharmaceutical StrategyInitiatives related to Covid-19: shortage of medicines\, dependency on raw materials from outside the EU\, cooperation between Member StatesFair competition between pharmaceutical companies in times of Covid-19 and Brexit\n\n\n\nWho should attend? \n\n\n\nIn-house counsel\, lawyers in private practice\, lawyers in national ministries and authorities dealing with regulation of the sector. \n\n\n\nInteractive online event \n\n\n\nThe conference will be hosted on ERA’s own online platform. You will be able to interact immediately and directly with our top-level speakers and other participants. We will make the most of the technical tools available to deliver an intensive\, interactive experience. As the platform is hosted on our own server\, the highest security settings will be applied to ensure that you can participate safely in this high-quality online conference. \n\n\n\n\n\n\n\nNetworking \n\n\n\nNetworking opportunities where participants can meet each other and chat with speakers will be offered. \n\n\n\nEuropaBio Members can benefit of a 25% discount on the price. Please liaise with Martina Cilia (m.cilia@europabio.org) to receive detailed information on the discount code.
URL:https://www.europabio.org/event/annual-conference-on-eu-law-in-the-pharmaceutical-sector/
LOCATION:VIRTUAL\, Metzer Allee 4\, Trier\, D-54295\, Germany
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-ERA.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210304T140000
DTEND;TZID=Europe/Brussels:20210304T153000
DTSTAMP:20210225T120052Z
CREATED:20210211T123919Z
LAST-MODIFIED:20210225T120052Z
UID:1355-1614866400-1614871800@www.europabio.org
SUMMARY:Measuring the Economic Footprint of the Biotechnology Industry in Europe
DESCRIPTION:Landscape and Positions for Economic Development: Industry and policy discussions to deliver biotechnology in Europe. \n\n\n\n\n\nEuropean GDP benefitted by €38.5 bn in 2018\, in the recent study from EuropaBio ‘Measuring the Economic Footprint of the Biotechnology Industry in Europe’.  The study looked at the economic impact of the biotechnology industry within the (then) 28 European member states\, in terms of gross value added (GVA)\, employment and trade.  Including spill over effects\, that number rises to €78.7bn.  The direct contribution adds up to about 1.5% of total industrial GVA within the countries assessed\, supported by 223\,000 direct jobs rising to over 700\,000 with associated employment. \n\n\n\nVery few other sectors enhance quality of life\, knowledge\, innovation\, productivity\, andenvironmental protection as biotechnology does.  \n\n\n\nJoin EuropaBio on March 4 to find out more about the the economic footprint of biotechnology in Europe and be part of the discussion on its role in future economic recovery and delivering healthy people and planet.
URL:https://www.europabio.org/event/measuring-the-economic-footprint-of-the-biotechnology-industry-in-europe-landscape-and-positions-for-development/
CATEGORIES:EuropaBio,Healthcare Biotech,Industrial Biotech
ATTACH;FMTTYPE=image/jpeg:https://www.europabio.org/wp-content/uploads/2021/02/WebEx-Event-Banner-WifOR.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210309T090000
DTEND;TZID=Europe/Brussels:20210312T170000
DTSTAMP:20210308T094328Z
CREATED:20210209T164320Z
LAST-MODIFIED:20210308T094328Z
UID:1289-1615280400-1615568400@www.europabio.org
SUMMARY:Immunology Virtual Partnering (Member Discount)
DESCRIPTION:Over 4% of the world’s population suffers from one or more of the over 80 autoimmune diseases identified to date. A large variety of treatment approaches have already been developed to curb the detrimental effects of autoimmune diseases\, and the market continues to flourish. In fact\, by 2025 this market is estimated to exceed a global value of $150 billion. \n\n\n\nAt Inova\, our aim is to facilitate the bridge between science and business. Inova and Biotechnology Innovation Organization (BIO)\, in partnership with Evaluate\, are organizing this Immunology Virtual Partnering Event. Through online one-to-one meetings taking place 9-12 March\, researchers\, biotechs and biopharmaceutical companies will discuss the latest research from immunology congresses\, pitch ideas and partner to prioritize the most promising research efforts. \n\n\n\nThis event will leverage Inova and Biotechnology Innovation Organization (BIO)’s biopharma industry expertise\, leading digital networking platform and years of experience organizing partnering events to connect scientific and business communities for the benefit of patients worldwide. \n\n\n\n\n\n\n\nEuropaBio Members can benefit from a 15% discount. Please liaise with Martina Cilia for further details. \n\n\n\n\n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/immunology-virtual-partnering-member-discount/
LOCATION:VIRTUAL\, 89 Rue Tronchet\, Lyon\, 69006\, France
CATEGORIES:External,Healthcare Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Immunology.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210310T140000
DTEND;TZID=Europe/Brussels:20210310T140000
DTSTAMP:20210308T093731Z
CREATED:20210308T092407Z
LAST-MODIFIED:20210308T093731Z
UID:1541-1615384800-1615384800@www.europabio.org
SUMMARY:All About RC(I) – Discussing the Renewable Carbon Strategy and Initiative
DESCRIPTION:Discuss the concept of renewable carbon and get answers to all your questions. Get to know the people and companies behind the Renewable Carbon Initiative and learn why your company should join. RCI members Cosun and UPM and nova-Institute will discuss and answer your questions. \n\n\n\nAbout the organizers \n\n\n\nThe Renewable Carbon Initiative (RCI) was initiated by nova-Institute after observing the struggles of the chemical and plastics industry facing the enormous challenges in meeting the climate goals set by the European Union and the sustainability expectations held by societies around the globe. It was clear that the industry has to go beyond using renewable energy. As decarbonisation is not an option for organic chemistry\, which is entirely based on the use of carbon\, an alternative strategy was needed. \n\n\n\n\n\n\n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/all-about-rci-discussing-the-renewable-carbon-strategy-and-initiative/
LOCATION:Virtual Event
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/03/Event-Banners-1.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210317T140000
DTEND;TZID=Europe/Brussels:20210317T160000
DTSTAMP:20210308T094239Z
CREATED:20210209T171912Z
LAST-MODIFIED:20210308T094239Z
UID:1296-1615989600-1615996800@www.europabio.org
SUMMARY:Empowering the Circular Bioeconomy through the EU Green Deal
DESCRIPTION:The 2020 Circular Economy Action Plan is one of the main blocks of the European Green Deal – Europe’s new agenda for sustainable growth – including initiatives along the entire life cycle of products and aiming at rendering sustainable products the norm in the EU. It focuses on boosting circular economy processes\, fostering sustainable consumption\, and safeguarding that the resources used are kept in the economy for as long as possible. In addition\, it remains committed to making circularity work for people\, regions\, and cities\, while leading global efforts on circular economy. \n\n\n\nAt the same time\, and closely linked with the above\, the bioeconomy offers great potential in contributing to tackle environmental and societal challenges\, such as resource efficiency\, climate change\, maintaining European competitiveness and job creation. The bioeconomy can therefore play a significant role in the EU Green Deal and particularly in the transition to a circular economy\, as outlined in a position paper developed by the European Bioeconomy Alliance. As a result\, this webinar aspires to address the above developments by providing an opportunity for discussion of how to best empower the circular bioeconomy through an enabling policy framework. \n\n\n\n\n\n\n\nEvent hosted by MEP Franc Bogovič\, Chair of the Bioeconomy Working Group of the European Parliament Intergroup on ‘Climate Change\, Biodiversity and Sustainable Development’. \n\n\n\n\n\n\n\nVIRTUAL EVENT
URL:https://www.europabio.org/event/empowering-the-circular-bioeconomy-through-the-eu-green-deal/
LOCATION:VIRTUAL\, Rue de la Science 10\, Brussels\, 1000\, Belgium
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-EUBA-Intergroup.png
ORGANIZER;CN="European Bioeconomy Alliance & EP Intergroup on CCBSD":MAILTO:ebcd.info@ebcd.org
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210318T110000
DTEND;TZID=Europe/Brussels:20210318T154500
DTSTAMP:20210212T162859Z
CREATED:20210128T095510Z
LAST-MODIFIED:20210212T162859Z
UID:903-1616065200-1616082300@www.europabio.org
SUMMARY:#EUIndustryWeek2021: BIO NRW
DESCRIPTION:Driving Change – How Green Chemistry and Digitalisation lead the way to a Sustainable EconomyThe focus of their event is green chemistry and sustainable processes\, focusing on how biotechnology and digitalization can contribute to the green transition. Watch the intervention from EuropaBio on on the EU perspective and what the industry suggests to drive innovation forward on the first day.
URL:https://www.europabio.org/event/bio-nrw-eu-industry-week/
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-BIO-NRW.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210318T160000
DTEND;TZID=Europe/Brussels:20210318T170000
DTSTAMP:20210212T162821Z
CREATED:20210128T145930Z
LAST-MODIFIED:20210212T162821Z
UID:957-1616083200-1616086800@www.europabio.org
SUMMARY:KeyGene’s two-part webinar on PanGenomes: needs\, value and applications (part 2)
DESCRIPTION:This two-part webinar on PanGenomes\, which Keygene organizes together with an academic partner and Allen Sessions from BASF\, will explain what one needs to construct PanGenomes and highlight their value in breeding and research. PanGenomes describe the available genetic diversity within\, for instance\, plant species\, crops or germplasm collections. Because of diminishing costs of genome sequencing\, increasing speed of reference genomes construction and advances in bioinformatics\, PanGenomes have become an accessible tool. The genome insights delivered by PanGenomes can spectacularly speed up and contribute to plant breeding and research.
URL:https://www.europabio.org/event/keygenes-two-part-webinar-on-pangenomes-needs-value-and-applications-part-2/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-KeyGene2.png
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210322T090000
DTEND;TZID=Europe/Brussels:20210325T170000
DTSTAMP:20210212T162759Z
CREATED:20210210T202010Z
LAST-MODIFIED:20210212T162759Z
UID:1331-1616403600-1616691600@www.europabio.org
SUMMARY:BIO-Europe Spring 2021
DESCRIPTION:The “must-attend” event series has gone digital\, and continues to grow from strength to strength\, proving its importance and relevance to the life science sector. Building on the success and momentum created by BIO-Europe Digital 2020 this past October our upcoming BIO-Europe Spring Digital will deliver more licensing opportunities\, more partnering meetings\, and more hot-off-the-press content than ever.    \n\n\n\nHere’s what will be different for 2021:    \n\n\n\nPRE-RELEASED CONTENT. The digital event will open 5 weeks early with on-demand content (panels\, company presentations and company showcases) to complement your partnering preparations and maximize your digital experience. partneringONE ALL in ONE. Our gold standard partnering platform has been transformed for the virtual era! With ONE login\, you access the entire event. No need to switch back and forth between platforms. Search by company or therapeutic area to discover potential partners and relevant conference sessions and company presentations.ONE SCHEDULE. To satisfy a truly global audience made up of thousands of delegates from more than 55 countries\, we provide one schedule that accommodates ALL TIME ZONES.   SOCIAL NETWORKING OPPORTUNITIES. We understand the value of networking outside of one-to-one meetings. In order to fill that void\, we created the “W
URL:https://www.europabio.org/event/1331/
CATEGORIES:External
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Bio-Europe-Spring.png
ORGANIZER;CN="EBD by InformaConnect":MAILTO:EBDcustomerservice@ebdgroup.com
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=Europe/Brussels:20210323T090000
DTEND;TZID=Europe/Brussels:20210324T170000
DTSTAMP:20210312T150444Z
CREATED:20210210T203214Z
LAST-MODIFIED:20210312T150444Z
UID:1337-1616490000-1616605200@www.europabio.org
SUMMARY:9th Conference on CO2-based Fuels and Chemicals
DESCRIPTION:The conference is one of the oldest and most established worldwide and has developed into a unique meeting place for the entire Carbon Capture & Utilisation (CCU) and Power-to-X industry and its customers. \n\n\n\nThe first day will focus on CO2-based transport and aviation fuels\, the second on CO2-based bulk and fine chemicals. CCU technologies are essential to meet the future demand for carbon from renewable sources. Take a look into the near future and exchange ideas with the leading pioneers. \n\n\n\nCCU is one essential pillar for the supply of renewable carbon besides biomass and recycling. The transition to direct CO2 utilisation as one alternative carbon source is needed to substitute fossil sources\, to fight climate change and to shift towards sustainable and climate-friendly production and consumption. For providing the full benefits of CCU technologies the use of renewable energy is indispensable. Especially the supply of green hydrogen is crucial for the production of CO2-based transportation and aviation fuels\, bulk and fine chemicals. \n\n\n\nA large number of European cross-sectoral projects for hydrogen production via large-scale electrolysers have been announced recently. The European Commission launched a 400 Billion hydrogen strategy for the full energy transition to renewable energies\, as well as for the further use of hydrogen in innovations and technologies such as the production of high-volume synthetic fuels and chemicals. \n\n\n\nMeanwhile\, 100 projects on CO2-based fuel and chemical production\, as well as efficient capture and utilisation technologies have been launched by several start-ups and established companies\, ranging from pilot over demonstration to commercial scale. Even more players show their interest in getting involved in CCU and are increasingly planning and implementing more plants on different scales for Power-to-X technologies\, low carbon fuels and a CO2-based chemistry. Great visions are becoming real business cases and innovations are starting to realise their potential! \n\n\n\nNew and leading players will showcase novel and improved applications based on the use of CO2 as feedstock. Main topics of the conference are green hydrogen production\, carbon capture technologies and carbon utilisation (Power-to-X): Transportation and aviation fuels\, building-blocks\, bulk and fine chemicals as well as advanced technologies for CO2 utilisation such as artificial photosynthesis.
URL:https://www.europabio.org/event/9th-conference-on-co2-based-fuels-and-chemicals/
LOCATION:NovaInstitute\, Chemiepark Knapsack Industriestraße 300\, Huerth\, 50354\, Germany
CATEGORIES:External,Industrial Biotech
ATTACH;FMTTYPE=image/png:https://www.europabio.org/wp-content/uploads/2021/01/Event-Banner-Cologne.png
END:VEVENT
END:VCALENDAR